<DOC>
	<DOC>NCT03062033</DOC>
	<brief_summary>Prospective study to quantify the prevalence of possible tardive dyskinesia (TD) in outpatient psychiatry practices in the United States (US), as well as to describe the associated disease burden in a cohort of patients with one or more psychiatric disorders and a cumulative lifetime exposure to antipsychotic medication of three months or more.</brief_summary>
	<brief_title>Real‐World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents</brief_title>
	<detailed_description />
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Movement Disorders</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Patient has a cumulative lifetime exposure to antipsychotic medication of three months or more Patient has a clinician confirmed diagnosis of one or more psychiatric disorder(s), as defined in the DSM‐5 Patient has a usual care clinic visit scheduled during the study recruitment window (i.e. a pre‐defined 2‐week period) Patient is able to read and understand English Patient is willing and able to comply with the study requirements Patient is unable to provide informed consent.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>